ORGO - Organogenesis Holdings Inc Stock Price, Fair Value and News

2.79USD-0.07 (-2.45%)Market Closed

Market Summary

USD2.79-0.07

Market Closed

-2.45%

ORGO Stock Price

View Fullscreen

ORGO RSI Chart

ORGO Valuation

Market Cap

368.2M

Price/Earnings (Trailing)

74.45

Price/Sales (Trailing)

0.85

EV/EBITDA

11.48

Price/Free Cashflow

56.18

ORGO Price/Sales (Trailing)

ORGO Profitability

Operating Margin

75.42%

EBT Margin

2.40%

Return on Equity

1.77%

Return on Assets

1.08%

Free Cashflow Yield

1.78%

ORGO Fundamentals

ORGO Revenue

Revenue (TTM)

433.1M

Rev. Growth (Yr)

-13.73%

Rev. Growth (Qtr)

-8.18%

ORGO Earnings

Earnings (TTM)

4.9M

Earnings Growth (Yr)

-107.59%

Earnings Growth (Qtr)

-117.95%

Breaking Down ORGO Revenue

Last 7 days

-5.1%

Last 30 days

1.8%

Last 90 days

-26.1%

Trailing 12 Months

40.7%

How does ORGO drawdown profile look like?

ORGO Financial Health

Current Ratio

2.8

ORGO Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	461.4M	457.3M	449.0M	433.1M
2022	461.9M	460.1M	463.2M	450.9M
2021	379.1M	433.4M	446.3M	467.4M
2020	422.4M	426.5M	463.0M	338.3M
2019	215.0M	236.4M	249.9M	417.8M
2018	194.2M	183.7M	183.0M	193.4M
2017	153.7M	168.6M	183.6M	198.5M
2016	0	0	0	138.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Organogenesis Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	freedman lori	sold (taxes)	-5,527	2.8	-1,974	chief admin. and legal officer
Apr 01, 2024	bilbo patrick	sold (taxes)	-6,991	2.8	-2,497	chief operating officer
Apr 01, 2024	gillheeney gary s.	sold (taxes)	-28,316	2.8	-10,113	president and ceo
Apr 01, 2024	grow brian	sold (taxes)	-5,535	2.8	-1,977	chief commercial officer
Apr 01, 2024	montecalvo antonio s.	sold (taxes)	-4,905	2.8	-1,752	vice president, health policy
Mar 28, 2024	bilbo patrick	acquired	179,655	1.18	152,250	chief operating officer
Feb 21, 2024	leibowitz arthur s	acquired	-	-	51,020	-
Feb 21, 2024	korfin michele ilene	acquired	-	-	51,020	-
Feb 21, 2024	giacomin jon l	acquired	-	-	51,020	-
Feb 21, 2024	gillheeney gary s.	acquired	-	-	685,131	president and ceo

Which funds bought or sold ORGO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	unchanged	-	-1,252	2,843	-%
Apr 15, 2024	Palumbo Wealth Management LLC	sold off	-100	-45,530	-	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	45.94	18,773	1,421,610	-%
Apr 05, 2024	CWM, LLC	added	106	5,000	18,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	49.00	49.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	45.06	10,173,200	21,925,400	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	50.02	803,893	1,668,700	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	31,321	142,802	-%
Feb 26, 2024	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	sold off	-100	-4,000	-	-%
Feb 26, 2024	Virtu Financial LLC	new	-	67,000	67,000	-%

Are Funds Buying or Selling ORGO?

Are funds buying ORGO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORGO

No. of Funds

Unveiling Organogenesis Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	morgan stanley	8.7%	11,505,331	SC 13G
Feb 02, 2024	soleus capital master fund, l.p.	6.8%	8,963,000	SC 13G/A
Apr 06, 2023	blackrock inc.	3.4%	4,488,613	SC 13G/A
Feb 14, 2023	soleus capital master fund, l.p.	5.6%	7,363,063	SC 13G/A
Feb 10, 2023	flynn james e	0%	0	SC 13G/A
Feb 03, 2023	blackrock inc.	8.5%	11,103,190	SC 13G/A
Oct 13, 2022	soleus capital master fund, l.p.	5.1%	6,626,063	SC 13G
Feb 11, 2022	flynn james e	6.57%	8,456,876	SC 13G/A
Feb 04, 2022	blackrock inc.	6.4%	8,239,832	SC 13G
Dec 30, 2021	ades alan a.	20.5%	26,375,746	SC 13D/A

Recent SEC filings of Organogenesis Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to Organogenesis Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.8B	85.2B	-7.62%	-10.06%	9.92	4.1	6.46%	95.94%
MRK	317.6B	60.1B	3.25%	9.20%	870.05	5.28	1.40%	-97.49%
PFE	143.5B	46.5B	-8.33%	-37.34%	-103.34	3.08	42.59%	-114.62%
AMGN	141.5B	28.2B	-2.53%	7.29%	21.07	5.02	7.09%	2.52%
GILD	83.4B	27.1B	-8.60%	-20.08%	14.73	3.08	-0.60%	23.36%
TEVA	14.8B	15.8B	-0.90%	54.57%	-25.67	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	0.13%	-17.24%	-320.54	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-12.75%	-17.88%	11.28	2.41	49.61%	324.78%
BHC	3.2B	8.8B	-7.68%	16.09%	-5.35	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-6.53%	-6.23%	14	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-10.42%	-30.36%	-3.78	1.79	24.65%	80.36%
TXMD	21.8M	1.3M	-17.83%	-48.08%	-2.12	16.74	-98.14%	-109.18%
ACRX	17.1M	-	-12.17%	23.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-33.93%	-94.71%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Organogenesis Holdings Inc News

Latest updates

Organogenesis Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-8.2%	100	109	117	108	116	117	121	97.00	128	114	123	103	107	101	69.00	62.00	232	64.00	65.00	57.00	64.00
Cost Of Revenue	7.7%	28.00	26.00	26.00	27.00	27.00	26.00	27.00	25.00	33.00	26.00	30.00	25.00	26.00	23.00	20.00	19.00	20.00	19.00	19.00	17.00	18.00
Gross Profit	-13.1%	72.00	83.00	91.00	81.00	88.00	91.00	95.00	72.00	95.00	88.00	93.00	77.00	81.00	78.00	49.00	43.00	54.00	45.00	46.00	40.00	46.00
Operating Expenses	-2.1%	73.00	75.00	81.00	85.00	80.00	89.00	83.00	72.00	76.00	71.00	70.00	64.00	60.00	55.00	51.00	58.00	56.00	53.00	53.00	52.00	51.00
S&GA Expenses	-4.4%	61.00	64.00	70.00	74.00	68.00	79.00	73.00	64.00	67.00	62.00	62.00	58.00	54.00	51.00	47.00	53.00	53.00	49.00	49.00	49.00	47.00
R&D Expenses	12.4%	12.00	10.00	11.00	11.00	11.00	10.00	10.00	9.00	8.00	9.00	7.00	6.00	6.00	4.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00
EBITDA Margin	-24.4%	0.05*	0.07*	0.05*	0.06*	0.06*	0.09*	0.11*	0.14*	0.16*	0.17*	0.20*	0.16*	-	-	-	-	-	-	-	-	-
Interest Expenses	13.2%	1.00	0.00	1.00	1.00	-0.03	1.00	1.00	1.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	3.00
Income Taxes	-127.5%	-1.23	4.00	4.00	-1.66	1.00	1.00	2.00	0.00	-32.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings Before Taxes	-123.5%	-1.80	8.00	9.00	-4.63	9.00	1.00	11.00	-0.87	19.00	13.00	21.00	10.00	19.00	21.00	-5.14	-16.28	-2.61	-10.69	-9.63	-15.63	-9.25
EBT Margin	-48.6%	0.02*	0.05*	0.03*	0.04*	0.04*	0.07*	0.09*	0.11*	0.13*	0.14*	0.16*	0.12*	-	-	-	-	-	-	-	-	-
Net Income	-118.0%	-0.57	3.00	5.00	-2.97	7.00	0.00	9.00	-0.91	51.00	13.00	21.00	10.00	18.00	21.00	-5.17	-16.31	-2.65	-10.74	-9.65	-15.67	-9.26
Net Income Margin	-60.6%	0.01*	0.03*	0.02*	0.03*	0.03*	0.13*	0.16*	0.18*	0.20*	0.14*	0.16*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	-32.2%	7.00	11.00	1.00	-12.64	-2.86	-4.95	4.00	-5.26	13.00	11.00	13.00	-6.26	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.6%	460	463	450	446	449	457	456	436	443	370	356	319	290	246	216	208	221	175	168	176	164
Current Assets	-0.2%	225	226	216	217	223	231	232	218	227	212	202	185	174	129	118	111	126	81.00	76.00	85.00	71.00
Cash Equivalents	5.7%	104	98.00	89.00	89.00	102	108	113	109	115	103	90.00	78.00	85.00	37.00	41.00	47.00	60.00	23.00	20.00	31.00	21.00
Inventory	1.2%	28.00	28.00	25.00	26.00	25.00	25.00	23.00	23.00	25.00	29.00	28.00	30.00	28.00	30.00	29.00	26.00	23.00	20.00	19.00	18.00	13.00
Net PPE	-1.1%	116	118	112	107	102	97.00	93.00	84.00	79.00	75.00	70.00	62.00	56.00	56.00	53.00	50.00	47.00	44.00	41.00	39.00	40.00
Goodwill	0%	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	3.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00
Liabilities	-2.4%	181	186	179	182	184	201	202	195	202	181	177	162	148	181	181	168	165	162	145	144	117
Current Liabilities	-1.2%	81.00	81.00	73.00	76.00	75.00	89.00	88.00	78.00	83.00	81.00	85.00	74.00	68.00	66.00	66.00	55.00	60.00	57.00	50.00	52.00	56.00
Shareholder's Equity	0.6%	279	277	271	264	266	256	254	242	241	189	175	153	142	61.00	32.00	40.00	52.00	13.00	23.00	33.00	40.00
Retained Earnings	-1.4%	-40.97	-40.40	-43.57	-48.88	-45.30	-52.79	-53.00	-61.75	-60.83	-111	-120	-140	-155	-171	-192	-187	-171	-166	-155	-145	-130
Additional Paid-In Capital	0.7%	320	317	315	313	311	309	307	303	302	301	299	298	297	237	228	228	227	179	178	178	177
Shares Outstanding	0.0%	131	131	131	131	131	131	130	129	128	128	128	128	-	-	-	-	-	-	-	-	-
Float	-	-	-	236	-	-	-	345	-	-	-	1,100	-	-	-	43.00	-	-	-	48.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-36.6%	10,613	16,735	8,646	-5,077	7,800	5,453	10,195	1,411	17,948	27,850	17,480	-1,300	23,215	8,869	-9,335	-17,283	-6,401	-5,453	-12,116	-9,558	-17,405
Share Based Compensation	-2.1%	2,366	2,417	2,299	1,914	1,855	1,702	1,692	1,303	1,083	1,041	1,042	698	497	486	469	209	236	242	234	224	255
Cashflow From Investing	44.4%	-3,324	-5,979	-7,499	-7,562	-10,656	-10,402	-6,168	-6,672	-5,227	-16,703	-4,333	-4,957	-5,418	-11,962	-1,875	-4,243	-3,458	-1,275	-1,184	-317	-362
Cashflow From Financing	-23.6%	-1,777	-1,438	-1,054	-1,236	-1,875	26.00	415	-765	-917	1,270	-798	-591	30,123	-775	4,890	8,230	47,070	9,728	2,796	19,133	13,285

ORGO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 433,140	$ 450,893	$ 467,359
Cost of goods sold	106,481	105,019	114,199
Gross profit	326,659	345,874	353,160
Operating expenses:
Selling, general and administrative	269,754	283,808	250,200
Research and development	44,380	39,762	30,742
Total operating expenses	314,134	323,570	280,942
Income from operations	12,525	22,304	72,218
Other expense, net:
Interest expense, net	(2,190)	(2,009)	(7,236)
Loss on the extinguishment of debt			(1,883)
Other income (loss), net	57	(13)	(13)
Total other expense, net	(2,133)	(2,022)	(9,132)
Net income before income taxes	10,392	20,282	63,086
Income tax (expense) benefit	(5,447)	(4,750)	31,116
Net income and comprehensive income	$ 4,945	$ 15,532	$ 94,202
Net income, per share:
Basic	$ 0.04	$ 0.12	$ 0.73
Diluted	$ 0.04	$ 0.12	$ 0.7
Weighted-average common shares outstanding
Basic	131,231,317	130,070,231	128,331,022
Diluted	132,746,727	132,383,152	133,662,659

ORGO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 103,840	$ 102,478
Restricted cash	498	812
Accounts receivable, net	81,999	89,450
Inventories	28,253	24,783
Prepaid expenses and other current assets	10,454	5,086
Total current assets	225,044	222,609
Property and equipment, net	116,228	102,463
Intangible assets, net	15,871	20,789
Goodwill	28,772	28,772
Operating lease right-of-use assets, net	40,118	43,192
Deferred tax asset, net	28,002	30,014
Other assets	5,990	1,520
Total assets	460,025	449,359
Current liabilities:
Current portion of term loan	5,486	4,538
Current portion of finance lease obligations	1,081
Current portion of operating lease obligations - related party	3,140	3,001
Current portion of operating lease obligations	10,004	8,707
Accounts payable	30,724	32,330
Accrued expenses and other current liabilities	30,074	26,447
Total current liabilities	80,509	75,023
Term loan, net of current portion	60,745	66,231
Finance lease obligations, net of current portion	1,888
Operating lease obligations, net of current portion - related party	17,227	20,367
Operating lease obligations, net of current portion	19,780	20,947
Other liabilities	1,213	1,122
Total liabilities	181,362	183,690
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued
Common stock, $0.0001 par value; 400,000,000 shares authorized; 132,044,944 and 131,647,677 shares issued; 131,316,396 and 130,919,129 shares outstanding at December 31, 2023 and 2022, respectively	13	13
Additional paid-in capital	319,621	310,957
Accumulated deficit	(40,971)	(45,301)
Total stockholders' equity	278,663	265,669
Total liabilities and stockholders' equity	$ 460,025	$ 449,359

About Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

CEO	Mr. Gary S. Gillheeney Sr.
WEBSITE	https://organogenesis.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1030

Organogenesis Holdings Inc Frequently Asked Questions

What is the ticker symbol for Organogenesis Holdings Inc? What does ORGO stand for in stocks?

ORGO is the stock ticker symbol of Organogenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organogenesis Holdings Inc (ORGO)?

As of Wed Apr 17 2024, market cap of Organogenesis Holdings Inc is 368.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORGO stock?

You can check ORGO's fair value in chart for subscribers.

What is the fair value of ORGO stock?

You can check ORGO's fair value in chart for subscribers. The fair value of Organogenesis Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Organogenesis Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Organogenesis Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ORGO is over valued or under valued. Whether Organogenesis Holdings Inc is cheap or expensive depends on the assumptions which impact Organogenesis Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORGO.

What is Organogenesis Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, ORGO's PE ratio (Price to Earnings) is 74.45 and Price to Sales (PS) ratio is 0.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGO PE ratio will change depending on the future growth rate expectations of investors.